Schwazze, Formerly Operating as Medicine Man Technologies, Inc., Provides Business Update and Announces Strong Third Quarter 2020 Financial Results

DENVER–(BUSINESS WIRE)–Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX:SHWZ) (“Schwazze ” or “the Company”), today provided a business update and announced strong financial results for its third quarter ended September 30, 2020.

Justin Dye, Chairman and Chief Executive Officer of Schwazze shared, “We are pleased with our progress in the third quarter. We continued to grow revenue and meaningfully narrow our net loss. Our third quarter performance demonstrates the team’s ability to implement our operating playbook and successfully integrate strategically attractive and accretive acquisitions such as Mesa Organics and Purplebee’s, which have proven to be an excellent strategic fit, into our operations.”

Dye continued, “We are eager to complete our acquisitions of Star Buds’ 14 Colorado locations during the fourth quarter. Star Buds is one of the most recognized and successful retail cannabis operators in North America. These acquisitions position us to become a cannabis leader in Colorado by combining their industry expertise with our best-in-class playbook. Together, we are creating the next era of cannabis that lowers the barrier of acceptance for mainstream America and accelerates innovation in health, happiness and quality of life for consumers.”

Business Update

  • On November 5, 2020, the Company announced that it has received satisfactory proof of funds acknowledgement from Star Buds in anticipation of closing the pending transactions. This acknowledgment enables companies to begin preparing for a fourth quarter 2020 closing of the acquisitions of 13 retail operations located throughout the Colorado front-range and one cultivation facility in Denver.
    • Star Buds is one of the most recognized and successful retail cannabis operators in North America based on revenue-per-location and profit. Upon completion of this transaction, the Company will be one the first publicly traded companies with full seed to sale operations in Colorado consisting of 17 dispensaries, manufacturing, and cultivation.
    • Based on the consolidated, unaudited 2019 results the Company received from Star Buds, these acquisitions collectively earned approximately $50M in revenue with a strong EBITDA margin.
    • The proforma revenue for the combined companies for 2020 will be approximately $90M and the combined companies will be profitable and cash flow positive after the completion of the acquisition.
  • On September 9, 2020, the Company announced that Nirup Krishnamurthy, Chief Integration and Information Officer, was named Chief Operating Officer, and Jeff Garwood, former GE executive, was appointed to the Schwazze Board of Directors.
    • Nirup Krishnamurthy has since assumed oversight of Schwazze’s business units including retail, manufacturing, cultivation, wholesale sales, and marketing to drive operational excellence throughout field operations. He has also continued to be responsible for the alignment and prioritization of the ongoing integration of the Company’s acquisitions and for driving technology innovation across the organization. Krishnamurthy joined Schwazze earlier this year, bringing more than 25 years of experience in operations, innovation, technology, integration and M&A at Fortune 500 companies including United Airlines, Northern Trust Bank and former grocery retailer The Great Atlantic & Pacific Tea Company (A&P).
    • Jeff Garwood is a recognized visionary business leader bringing 30 years of extensive experience across
Read More

Editas Medicine Announces Third Quarter 2020 Results and Update

EDIT101 for LCA10 BRILLIANCE trial adult low-dose cohort completed

EDIT-301 for sickle cell disease on track for IND filing by end of 2020

EDIT-201 for solid tumors preclinical data to be presented at SITC and ASH

Cash, cash equivalents, and marketable securities of $541 million as of September 30, 2020

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2020.

“We were pleased to regain full operating control of our ocular programs per our new agreement with AbbVie, which provides us with important flexibility. We have finished dosing the first cohort with EDIT-101 in the landmark BRILLIANCE trial and enrollment remains active,” said Cynthia Collins, Chief Executive Officer of Editas Medicine.

Ms. Collins continued, “The advancements in our ocular portfolio are complemented by the strategic development of our engineered cell medicines. We are on track to file the IND for EDIT-301 for sickle cell disease in the fourth quarter and are eager to present additional data on this potentially best-in-class medicine and our large-scale manufacturing process at the upcoming American Society of Hematology Annual Meeting. Substantial progress has also been made in the development of EDIT-201, an allogeneic NK cell medicine to treat solid tumors. Preclinical data to be presented at ASH show enhanced tumor killing with EDIT-201 compared to unedited NK cells, and additional data on this program will be featured at the upcoming Society for Immunotherapy of Cancer’s Annual Meeting.”

Recent Achievements and Outlook

In Vivo CRISPR Medicines  

  • EDIT-101 for LCA10
    BRILLIANCE Phase1/2 adult low-dose cohort completed
    Editas Medicine (Company) has completed dosing of the first cohort of adult patients with visual light perception only administered the low dose of EDIT-101. Trial enrollment remains active but has experienced a slowdown due to the ongoing impact of the COVID-19 pandemic. 

  • Ocular Medicines
    Regained full control of ocular medicines
    Editas Medicine terminated its 2017 agreement with Allergan, now part of AbbVie, and entered a new agreement with AbbVie that returned development and commercialization rights for ocular medicines to Editas Medicine. As part of the new agreement, AbbVie has transferred supplier contracts, including with the contract research organization (CRO), as well as sponsorship of the investigational new drug application (IND) for the BRILLIANCE Phase 1/2 clinical trial to Editas Medicine. The Company plans to continue to advance ocular medicines, including EDIT-101 for Leber congenital amaurosis 10 (LCA10).

Ex Vivo CRISPR Cell Medicines  

  • EDIT-301 for Sickle Cell Disease and Beta-Thalassemia
    On track for IND filing by end of 2020
    Editas Medicine continues to prepare for a Phase 1/2 clinical trial evaluating EDIT-301 for the treatment of sickle cell disease. The Company has completed preclinical toxicology studies, identified a lead principal investigator, and engaged a CRO. Clinical trial materials are being manufactured by Editas Medicine. The Company remains on track to file an IND for the treatment of sickle cell disease by

Read More

James Carville Tells Democrats Stay Calm Waiting for Results

Democratic strategist James Carville was urging calm in a late Tuesday evening MSNBC appearance, telling Democrats to “just put the razor blades and Ambien back in the medicine cabinet — we’re going to be fine.”

The situation that had Carville acting in contravention to his famous “Ragin’ Cajun” nickname was several early swing states going for President Donald Trump over Joe Biden, including Florida. Carville nonetheless remained unfazed, and urged his fellow Democrats to follow his example.

“First thing is every Democrat — just put the razor blades and the Ambien back in the medicine cabinet,” Carville told anchor Brian Williams. “We’re gonna be fine, we’re gonna be fine.”

Carville pointed to Michigan and Pennsylvania still looking hopeful for the Democrats, and Biden’s stronger-than-expected showing in Georgia so far. He acknowledged that he had boldly predicted an early result just yesterday, but still “I think we’re going to be just fine.”

“I’m very optimistic,” Carville continued. “People are rerunning the numbers. And we just have to hang in there, and we’re going to win this thing. I promise you.”

Carville made a reference to the bottle of bourbon seen on a table behind him, a bottle of Pappy Van Winkle’s Family Reserve, a highly-sought-after brand that is regarded as one of the finest bourbons in the world.

“I think I’ll be able to crack it open, maybe not tonight as I hoped, but I will crack that little puppy open before this is over.”

After discussing some of the state results so far, Williams again turned the conversation to the bourbon. “I’m duty bound to ask if the bottle behind you started the night full.”

“Well, no. That’s stuff is about $200 an ounce, and I parsed it out pretty good, so I’ll be — Uncle Pappy, he’s not coming out until I’m sure, but right now I feel good,” said Carville, noting that he felt good about the numbers in Pennsylvania, and the areas in Georgia where there were still outstanding votes were also favorable for Biden.

“Everybody hang in there. We’re just going to be fine. We’ve got to have the attitude of a winner here, and we’re going to be a winner.”

Watch above, via MSNBC.

Have a tip we should know? [email protected]

Source Article

Read More

Prop. 23 aimed at dialysis industry trailing in early results

INGLEWOOD, CA. AUGUST 28, 2014 --- Giraldo Garcia, 54, gets dialysis at DaVita Dialysis Center on August 28, 2014 in Inglewood. (Irfan Khan / Los Angeles Times)
Giraldo Garcia, 54, receives dialysis treatment at DaVita Dialysis Center in Inglewood in 2014. ( Los Angeles Times)

A $100-million effort to impose new regulations on the dialysis industry appeared to be heading for defeat in early results Tuesday.

Proposition 23 would require dialysis clinics to employ at least one doctor who would be on site whenever patients are receiving treatment. Supporters of the measure, including the Service Employees International Union-United Healthcare Workers West, said dialysis clinics were putting profits over patient care by not having a doctor available in the event of complications or an emergency.

Opponents, however, argued the measure was the latest attempt by SEIU-UHW to weaponize the ballot box to try to force the dialysis industry to spend millions to defend itself when the union’s real interest is getting clinic workers to unionize. The dialysis industry put more than $100 million into fighting the measure, saying the unnecessary added cost would lead to dialysis clinics closing, which would put patients at risk.

In California, there are roughly 600 dialysis clinics treating thousands of people suffering from kidney failure with machines that remove a patient’s blood and filter it to remove waste and excess fluids before returning the blood to their body. Patients typically require dialysis three days a week for about four hours a day in order to live. Due to the high demand for dialysis, clinic operators say they are typically open six days a week for up to 16 hours a day.

In addition to having a doctor on site at all times, Proposition 23 would require clinics to report dialysis infection information to the California Department of Public Health every three months, which would be posted on the state agency’s website. Clinics could face a fine of up to $100,000 for failing to report the data or reporting inaccurate information.

Clinics are currently required to report dialysis infection-related information to the U.S. Centers for Disease Control and Prevention.

The measure would also require clinics to obtain approval from the state’s public health department before closing or substantially reducing services. Proposition 23 would bar clinics from refusing access to a patient based on their insurance.

Most people on dialysis in California are covered by Medicare, which extends coverage to people with kidney failure regardless of age or disability status.

This story originally appeared in Los Angeles Times.

Source Article

Read More

Oregon Measure 110 on drug recovery treatment: live results

  • Measure 110 in Oregon would provide drug recovery services partially funded through marijuana taxes. 
  • Polls in Oregon closed at 11 p.m. ET.
  • The measure would also reclassify the penalties for specified drugs.
  • Insider will have live results on the propositions as soon as they come in.
  • Visit Business Insider’s homepage for more stories.

Polls in Oregon closed at 11 p.m. ET.

Oregon’s 2020 ballot includes Measure 110, which would provide statewide drug recovery services partially funded by marijuana taxes and would reclassify the penalties for certain drugs.

The text for Oregon Measure 110 reads as follows:


Measure mandates establishment/ funding of “addiction recovery centers” (centers) within each existing coordinated care organization service area by October 1, 2021; centers provide drug users with triage, health assessments, treatment, recovery services. To fund centers, measure dedicates all marijuana tax revenue above $11,250,000 quarterly, legislative appropriations, and any savings from reductions in arrests, incarceration, supervision resulting from the measure. Reduces marijuana tax revenue for other uses. Measure reclassifies personal non-commercial possession of certain drugs under specified amount from misdemeanor or felony (depending on person’s criminal history) to Class E violation subject to either $100 fine or a completed health assessment by center. Oregon Health Authority establishes council to distribute funds/ oversee implementation of centers. Secretary of State audits biennially. Other provisions.

Result of “Yes” Vote

“Yes” vote provides addiction recovery centers/services; marijuana taxes partially finance (reduces revenues for other purposes); reclassifies possession of specified drugs, reduces penalties; requires audits.

Result of “No” Vote

“No” vote rejects requiring addiction recovery centers/services; retains current marijuana tax revenue uses; maintains current classifications/ penalties for possession of drugs.

Source Article

Read More

Warmer world linked to poor pregnancy results: study

Women exposed to high temperatures and heatwaves during pregnancy are more likely to have premature or stillborn babies, researchers said Wednesday.

Such outcomes — closely linked to poverty, especially in the tropics — will likely increase with global warming, especially during more frequent and intense heatwaves, they reported in BMJ, a medical journal.

Even small increases “could have a major impact on public health as exposure to high temperatures is common and escalating,” the study concluded.

Each year, 15 million babies are born premature, the leading cause of death among children under five, according to the World Health Organization (WHO). 

That mortality is concentrated in the developing world, especially Africa. 

To quantify the impact of higher heat on pregnancy outcomes, an international team of researchers led by Matthew Chersich from Wits Reproductive Health and HIV Institute in Johannesburg looked at 70 peer-reviewed studies of 27 rich, poor and middle-income nations.

Of the 47 studies that concerned preterm births, 40 reported they were more common at higher temperatures.

The odds of a preterm birth rose, on average, by five percent per one degree Celsius (1C) increase, and by 16 percent during heatwave days, according to the new findings.

Global warming has seen Earth’s average temperature rise by 1C over the last century, with greater increases over large land masses.

The number of exceptionally hot days are expected to increase most in the tropics, according to the UN’s climate science advisory panel, the IPCC.

– ‘High risk’ for heat –

Extreme heatwaves — made more dangerous by high humidity — are projected to emerge earliest in these regions as well.

Limiting global warming to 1.5C instead of 2C — goals consistent with the Paris Agreement — would mean around 420 million fewer people frequently exposed to extreme heatwaves, the IPCC said in a 2018 report.

The new study also found that stillbirths increased by five percent per 1C increase in temperature, with the link most pronounced in the last few weeks of pregnancy.

The impact of warmer days and heatwaves on low birth weight, which is associated with a host of health problems later in life, was smaller, but still significant, the researchers said.

As expected, adverse pregnancy outcomes associated with rising temperatures were strongest among poorer women.

Because other factors such as pollution might play a role in stillbirths and premature babies, the role of warmer temperatures is hard to pin down, the researchers acknowledged.

Nonetheless, the findings are strong enough to suggest that pregnant women “merit a place alongside the groups typically considered as at ‘high risk’ for heat-related conditions,” they concluded.

More research and targeted health policies should be a high priority, they added.


Source Article

Read More

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentation of body composition data from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS). The results were presented today by Parisa Salehi, M.D., Clinical Director of the Prader-Willi Syndrome Clinic at Seattle Children’s Hospital, in a late-breaking oral presentation at The Obesity Society’s ObesityWeek® 2020 meeting. Dr. Salehi presented the data on behalf of the DESTINY PWS Investigators.

DESTINY PWS is a randomized, double-blind, placebo-controlled Phase III study of once daily oral administration of DCCR in 127 PWS patients conducted at 29 sites in the U.S. and U.K. The objective of the study was to assess the efficacy and safety of DCCR in subjects with genetically-confirmed PWS aged four years and older and weighing between 20 and 134 kg. Patients who completed the double-blind study enrolled in study C602, an ongoing open-label, extension study. Updated top-line results were previously announced in September 2020 that demonstrated DCCR’s beneficial impact on hyperphagia, the predominant symptom of PWS, other behaviors and body composition abnormalities typical of PWS.

Key results for effects on body composition and adipokines following DCCR treatment were presented at ObesityWeek 2020 as follows:

Fat mass and body mass:

  • Significant reductions in fat mass (p=0.0027) were observed after 13 weeks of double-blind treatment
    –  Greater mean reductions in fat mass were observed in those participants weighing more than 100 kg at baseline (placebo-adjusted difference -4.82 kg)

  • Linear exposure-response relationship for fat mass was significant with greater fat loss occurring at higher circulating drug concentrations (p<0.0001)

  • Trend towards increased lean body mass for DCCR compared to placebo (p=0.058)

  • Significant increase in lean body mass/fat mass ratio (p=0.001)


  • Significant reduction in leptin while it increased in placebo-treated subjects (p<0.0001)

  • Linear exposure-response relationship for leptin was significant with greater reductions in leptin occurring at higher circulating drug concentrations (p<0.0001)

  • Reductions in leptin were greater than would be predicted solely by the loss of body fat, suggesting an improvement in leptin sensitivity


  • Adiponectin, a cardioprotective hormone, increased in DCCR-treated subjects, but decreased in placebo-treated participants (p<0.0001)

“We are pleased to present further results from the DESTINY PWS study that demonstrate DCCR’s effect on body composition. In the DCCR group compared to placebo, we have observed a significant reduction in fat mass and leptin. Improvements in leptin sensitivity, as suggested by the results, may have an important impact on regulating hyperphagia,” said Dr. Salehi. “The data presented to date show that DCCR has the potential to manage both behavioral and co-morbid metabolic components of PWS.”

“These data represent additional means by which DCCR may address the significant unmet medical needs and the life-threatening comorbidities associated with PWS,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We remain focused on advancing DCCR as a potential treatment

Read More

New Hampshire Reports Record High Positive COVID-19 Test Results

CONCORD, NH — Gov. Chris Sununu, R-NH, issued a weekend statement Saturday after state health officials reported the highest single day of new COVID-19 positive test results — 205, including 31 children.

The new test results were reported after 7,927 specimens were collected Friday and prior days of tests were updated slightly from previous reports. A little more than 1,100 test results are pending for a polymerase chain reaction test positivity rate of 1.6 percent.

“The situation here in New Hampshire remains very serious, the data shows that community transmission is increasing, and we expect cases to rise,” Sununu said. “We must all remain vigilant in our daily lives. As we enter these winter months, it will be more important than ever to wear your mask, practice social distancing, and maintain proper hand hygiene.”

Nearly a quarter of the new test results, 50, came from Rockingham County with 27 living in Hillsborough County outside of Manchester and Nashua, 19 residing in Nashua, and 13 living in Merrimack.

State officials are still investigating the residency of eight cases.

Fifty-three percent of the new positive test results were female.

The state reported that 42 people are currently hospitalizations while only one of the new cases has no identified risk factors.

Accumulatively, 11,084 people have contracted COVID-19 in New Hampshire with 1,338 currently infected and 9,263, 84 percent, having recovered from the virus.

The State Joint Information Center also announced the 483rd death in the New Hampshire — a woman who was 80 years of age or older and lived in a long-term care setting in Hillsborough County.

More than 345,000 people have been tested for the coronavirus with nearly 617,00 PCR tests being administered by the state and 4,400 people under public health monitoring.

More Possible Restaurant Exposures

Both state and Nashua health officials issued alerts during the past 24 hours about possible restaurant exposure to the public.

Nashua Public Health is investigating potential community exposure related to a person with a confirmed COVID-19 diagnosis at the Texas Roadhouse on 580 Amherst St. The potential community exposure occurred in the bar area between 3 and 10 p.m. on Oct. 22, and 11 a.m. to close on Oct. 23.

“The health and safety of our staff and customers is our top priority,” Eric Martin, the restaurant’s director of food safety. “We have been following CDC guidelines for cleaning and disinfecting our facility. We follow all reopening guidance for food service establishments from the state.”

Public health is investigating the situation and notifying any known close contacts directly but if you were at the restaurant during those dates, you should self-quarantine, monitor for symptoms — sore throat, congestion, runny nose, headache, muscle ache, fatigue, new loss of taste or smell, fever, cough, shortness of breath, nausea, vomiting, or diarrhea, and get tested.

State health officials said contact tracers were investigating another possible community exposure in Merrill’s Tavern and Stagecoach Grille at the Atkinson Resort & Country Club between 11 a.m. and 11:30

Read More

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology

Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, announced today that results from two pivotal Phase 3 studies evaluating setmelanotide in proopiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity were published in The Lancet Diabetes & Endocrinology. As previously reported, data from the studies demonstrate that treatment with setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, led to statistically significant and clinically meaningful reductions of weight and hunger.

“Results from Rhythm’s pivotal Phase 3 studies, which are the largest studies to date in POMC and LEPR deficiency obesities, provide evidence regarding the safety and efficacy of setmelanotide and we believe they validate its potential long-term use as a novel treatment for severe obesity and hyperphagia,” said co-author Peter Kühnen, M.D., Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Germany. “It is important to recognize the signs of these rare genetic disorders because we may soon have a targeted treatment option available for the first time for obesity disorders caused by impairments of the MC4R pathway.”

Rhythm initially reported positive topline data from the Phase 3 studies in August 2019 and subsequently presented updated data in a late-breaking research forum during the 37th Annual Meeting of The Obesity Society at ObesityWeek® 2019.

Eight of 10 participants with POMC deficiency obesity (80%; P<0.0001 compared with historical data) and five of 11 participants with LEPR deficiency obesity (45%; P=0.0001 compared with historical data) achieved at least 10 percent weight loss at approximately one year. The mean percent change in “most hunger” score in participants aged 12 years and older was -27.1 percent (n=7; P=0.0005) in POMC deficiency obesity and -43.7 percent (n=7; P<0.0001) in LEPR deficiency obesity. Consistent with prior clinical experience, setmelanotide was generally well-tolerated in both trials. The most common adverse events were injection site reaction, skin hyperpigmentation, and nausea.

“These results are significant because, as we know from natural history data, individuals living with POMC or LEPR deficiency obesity consistently experience substantial weight gain each year beginning in early childhood, and we would not expect any of these patients to be able to achieve 10 percent weight loss over the course of a year without continued treatment,” said co-author Karine Clément, professor of nutrition at Pitié-Salpêtrière hospital and Sorbonne University in Paris. “These data and the significant unmet need to address the obesity and hyperphagia caused by rare genetic disorders of obesity underscore the importance of testing for genetic variants that may impair MC4R activation and lead to severe obesity.”

In May 2020, Rhythm announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application (NDA) for setmelanotide for the treatment of POMC deficiency obesity and LEPR deficiency obesity, granted Priority Review of the NDA and assigned a Prescription Drug

Read More

Study: 30% of nursing facilities in COVID-19 ‘hot spots’ wait 3 days or more for test results

Oct. 30 (UPI) — Nearly one-third of skilled nursing facilities situated in COVID-19 hot spots across the United States still are waiting three days or more for virus test results for staff and residents as of the end of September, according to a report published Friday by JAMA Internal Medicine.

Nationally, just under 40% of all of these facilities — which including residential and rehabilitation centers staffed with nurses, physical and occupational therapists, speech pathologists and audiologists — indicated that it took three days or more to receive COVID-19 test results for residents and staff, the data showed.

The findings were as of Sept. 27, or more than two months after Medicare began to distribute rapid, point-of-care tests to generate results in one day or less to these facilities, the researchers said.

While the number of facilities receiving test results in a day or less doubled in some areas during September, researchers say the progress is not sufficient enough.

“Rapid testing turnaround is critical to prevent outbreaks in nursing homes — and elsewhere — but only a tiny fraction of homes have access to turnaround that is less than one day,” study co-author Dr. Michael L. Barnett told UPI.

“With slower turnaround, staff with COVID-19 and no symptoms will circulate in a facility and spread infection before the positive test comes back,” said Barnett, assistant professor of health policy and management at Harvard T. H. Chan School of Public Health.

Nursing homes and assisted-living facilities across the country were hit hard by the COVID-19 pandemic, particularly in the spring, accounting for 40% of all virus-related deaths nationally, according to the Kaiser Family Foundation.

As a result, the U.S. Centers for Medicare and Medicaid Services began to distribute “rapid” virus testing kits to these facilities in July. The tests could be administered on-site and provide results in one day or less, agency officials said.

The agency requires facilities located in areas with low rates — less than 5% — of COVID-19 transmission to test residents and staff members monthly.

However, those based in hot spots — with up to 10% or more of virus transmission — should be testing staff and residents at least twice weekly, according to officials.

For this analysis, Barnett and his colleagues analyzed data from 15,065 — or 98% — of the skilled nursing facilities included in the Medicare COVID-19 Nursing Home Database. The database is a federally mandated weekly assessment of all Medicare-certified facilities, to examine facility-reported test result turnaround time.

As of Sept. 27, 14% of all facilities nationally said they received COVID-19 test results for staff members in one day or less, up from 6.2% three weeks earlier, the data showed.

By that same date, 10% of facilities reported getting test results for residents in one day or less, an increase from 5% earlier in the month.

In “hot spot counties” — with high rates of community spread of the virus — the number of facilities that reported test turnaround of one day or

Read More